Peripheral Artery Disease

Global Peripheral Artery Disease Market to Reach US$7.0 Billion by 2030

The global market for Peripheral Artery Disease estimated at US$4.7 Billion in the year 2024, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Devices, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Drugs segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 10.9% CAGR

The Peripheral Artery Disease market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Peripheral Artery Disease Market – Key Trends & Drivers Summarized

Why Is Peripheral Artery Disease Gaining Attention as a Major Global Cardiovascular Health Concern?

Peripheral Artery Disease (PAD), characterized by the narrowing or blockage of arteries—primarily in the lower extremities—due to atherosclerotic plaque buildup, is increasingly being recognized as a critical global health issue. Affecting over 200 million people worldwide, PAD not only impairs mobility and quality of life but also significantly elevates the risk of myocardial infarction, stroke, and limb amputation. Its growing prevalence, particularly among aging populations, diabetics, and smokers, underscores the need for early diagnosis, aggressive risk factor management, and accessible treatment options.

What makes PAD particularly challenging is its underdiagnosis and frequent misidentification as a symptom of aging or arthritis, leading to delayed interventions. As public awareness increases and screening protocols improve, the demand for diagnostic imaging, vascular assessments, and minimally invasive therapies is accelerating. Health systems worldwide are now integrating PAD detection into routine cardiovascular care and diabetes management programs, propelling clinical focus and therapeutic innovation aimed at reducing complications and improving long-term vascular outcomes.

How Are Therapeutic Advances and Minimally Invasive Devices Shaping PAD Management?

Modern PAD treatment is moving beyond systemic pharmacotherapy to include advanced endovascular interventions and biologically engineered therapeutic strategies. Antiplatelet agents, lipid-lowering drugs, and antihypertensives remain foundational in risk mitigation. However, device-based interventions such as balloon angioplasty, drug-eluting stents (DES), atherectomy systems, and drug-coated balloons (DCBs) are being increasingly adopted for revascularization, especially in patients with lifestyle-limiting claudication or critical limb ischemia (CLI).

Technological innovation is enhancing device design with features like ultrathin strut platforms, bioresorbable polymers, and targeted drug release mechanisms to reduce restenosis and improve vessel patency. Adjunctive tools such as intravascular ultrasound (IVUS), optical coherence tomography (OCT), and perfusion imaging are improving procedural accuracy and post-operative monitoring. Meanwhile, regenerative therapies involving autologous stem cells and angiogenic growth factors are under clinical evaluation for complex and non-reconstructable PAD cases. These advancements are shifting the treatment paradigm toward personalized, limb-salvaging, and less invasive management.

Which Risk Groups and Global Health Systems Are Driving Demand for PAD Diagnostics and Interventions?

PAD is most prevalent among individuals over 65, smokers, patients with diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease. The growing burden of noncommunicable diseases and sedentary lifestyles in urban populations is pushing PAD further into public health focus. Veterans, amputees, and post-operative patients also form significant segments requiring vascular monitoring and rehabilitative care. As multidisciplinary care models expand, PAD is increasingly managed in collaboration with cardiologists, diabetologists, vascular surgeons, and primary care providers.

North America and Western Europe lead the market in terms of diagnosis and intervention rates, owing to structured vascular programs, reimbursement coverage, and widespread access to endovascular labs. However, Asia-Pacific—particularly China, India, and Japan—is witnessing the fastest growth in PAD interventions due to demographic shifts, rising diabetes prevalence, and improving healthcare infrastructure. Public health agencies in Latin America and Africa are beginning to recognize PAD as a target for noncommunicable disease strategies, driving investments in screening campaigns, training, and device accessibility.

What Is Driving Long-Term Growth and Strategic Innovation in the PAD Treatment Market?

The growth in the peripheral artery disease market is driven by a convergence of aging demographics, rising comorbidity rates, and innovations in both pharmaceutical and interventional therapies. As PAD gains recognition as a systemic vascular disorder with far-reaching consequences, healthcare stakeholders are increasingly prioritizing early detection, long-term surveillance, and cost-effective interventions. Patient engagement platforms, telemonitoring, and wearable diagnostics are also being integrated into PAD management to improve adherence and remote tracking.

Strategically, companies are developing next-generation drug-device combinations, bioabsorbable implants, and AI-powered imaging tools to optimize procedural outcomes and reduce recurrence. Partnerships between medtech firms, academic institutions, and public health bodies are fostering clinical trials and health economic studies to validate emerging therapies. As value-based care models emphasize quality-adjusted life years (QALYs) and limb salvage outcomes, the PAD market is expected to continue its trajectory as a key focus within the broader cardiovascular therapeutics landscape.

SCOPE OF STUDY:

The report analyzes the Peripheral Artery Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Devices, Drugs); End-User (Specialty Clinics, Hospitals)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• AngioDynamics
• B. Braun Melsungen AG
• Bayer AG
• Becton, Dickinson and Company
• Biotronik
• Boston Scientific Corporation
• Cardinal Health
• Cook Medical
• Cordis
• Endologix, Inc.
• Johnson & Johnson MedTech
• LeMaitre Vascular
• Medtronic plc
• Merit Medical Systems
• OrbusNeich
• Philips Healthcare
• Shockwave Medical
• Straub Medical AG
• Terumo Corporation

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.